Amgen reported a 7% revenue increase in Q1, driven by strong international performance and strategic acquisitions, while maintaining full-year guidance. Management expressed confidence in their robust pipeline and ongoing cost-saving measures, despite minor challenges like inventory drawdowns. The positive financial outlook and pipeline developments are likely to support a favorable short-term sentiment for the stock.

[1]